Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 10:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 292 matching trials from the live ClinicalTrials.gov search.
Conditions
Idiopathic Short Stature
Interventions
Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
12 Years to 18 Years · Male only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Jacksonville, Florida • Orlando, Florida • Philadelphia, Pennsylvania
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Lung Cancer, Non Small Cell Lung Cancer (NSCLC), Breast Cancer, Estrogen Receptor Breast Cancer
Interventions
entinostat, Erlotinib, Exemestane
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
18 Years to 90 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
3
States / cities
Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee
Conditions
Metastatic Breast Cancer
Interventions
Enobosarm, Exemestane
Drug
Lead sponsor
Veru Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
34
States / cities
Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more
Conditions
Breast Cancer Female
Interventions
tamoxifen, letrozole, anastrozole, or exemestane, Patient reported outcomes
Drug · Behavioral
Lead sponsor
Shayna Showalter, MD
Other
Eligibility
65 Years and older · Female only
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Charlottesville, Virginia • Richmond, Virginia
Conditions
Breast Neoplasm Female, Arthralgia, Aging
Interventions
Aromatase inhibitor
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Single Dosing of Zoledronic Acid in Cancer Therapy Induced Bone Loss (CTIBL)

NCT00712985
Conditions
Breast Cancer
Interventions
Zometa
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Breast Cancer
Interventions
Value Affirmation, Reflective Journaling
Behavioral
Lead sponsor
Carnegie Mellon University
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib + an aromatase inhibitor, Aromatase inhibitor
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
New York, New York
Conditions
Breast Cancer
Interventions
Fulvestrant, GDC-0941, GDC-0941 Matching Placebo, GDC-0980, GDC-0980 Matching Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
41
States / cities
Birmingham, Alabama • Hayward, California • Oakland, California + 35 more
Conditions
Metastatic Breast Cancer
Interventions
Palbociclib + an aromatase inhibitor, Palbociclib + Letrozole, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
New York, New York
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions
Abemaciclib, Anastrozole, Fulvestrant, Letrozole, Palbociclib, Ribociclib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Breast Cancer
Interventions
TOL2506, Tamoxifen, Letrozole tablets, Anastrozole Tablets, Exemestane Tablets
Drug
Lead sponsor
Tolmar Inc.
Industry
Eligibility
18 Years to 51 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
17
States / cities
Greenbrae, California • Fort Lauderdale, Florida • Lexington, Kentucky + 14 more
Conditions
Breast Cancer, Arthralgia
Interventions
Not listed
Lead sponsor
Lynn Henry
Other
Eligibility
21 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Premenopausal, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Adenosine, Magnetic Resonance Imaging, Regadenoson, Stress Management Therapy
Biological · Procedure · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Up to 55 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Breast Cancer
Interventions
surveys completed by subject
Other
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years to 60 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
San Diego, California
Conditions
Polyostotic Fibrous Dysplasia, Precocious Puberty
Interventions
Testolactone
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1982 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Atrophic Vaginitis, Breast Cancer
Interventions
Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2024
U.S. locations
5
States / cities
Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more
Conditions
Locally Advanced Breast Cancer, Metastatic Breast Cancer
Interventions
Fulvestrant, Exemestane
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
32 Years to 91 Years · Female only
Enrollment
694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Arcadia, California • Fountain Valley, California + 48 more
Conditions
HER2-Positive Breast Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7
Interventions
Aromatase Inhibition Therapy, Carboplatin, Cytology Specimen Collection Procedure, Docetaxel, Goserelin Acetate, Laboratory Biomarker Analysis, Pertuzumab, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Trastuzumab, Whole Breast Irradiation
Drug · Other · Biological + 2 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2025
U.S. locations
731
States / cities
Fairbanks, Alaska • Hot Springs, Arkansas • Anaheim, California + 466 more
Conditions
HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
Interventions
AVZO-021, Fulvestrant, Letrozole, AVZO-023
Drug
Lead sponsor
Avenzo Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
16
States / cities
Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
Conditions
Breast Cancer, ER Positive Breast Cancer
Interventions
Letrozole 2.5mg
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
178 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
Lebanon, New Hampshire
Conditions
Breast Cancer
Interventions
anastrozole
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Ann Arbor, Michigan